{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:51:38Z","timestamp":1793105498939,"version":"4.5.0"},"reference-count":15,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clear cell renal cell carcinoma (RCC) is commonly associated with alterations in the VHL tumor suppressor gene, resulting in upregulation of hypoxia-inducible factor pathways. Immune checkpoint inhibitors and vascular endothelial growth factor inhibitors are the mainstays of systemic treatment for metastatic RCC; however, most patients encounter disease progression after the initial response. The phase 3 clinical trial LITESPARK-005\u2013belzutifan (HIF-2\u03b1 inhibitor) demonstrated improvement in progression-free survival compared with everolimus in heavily pretreated patients unselected for somatic\/germline VHL alterations (an objective response rate of 23% and a median time on therapy of 7.6 months in the belzutifan cohort), resulting in U.S. FDA approval for patients with advanced RCC. Herein, we present two cases of refractory metastatic RCC (including one with brain metastases) with somatic VHL mutations who received belzutifan after discussion in the institutional Molecular Tumor Board. Both patients had an excellent clinical response (partial remissions ongoing at &amp;gt;12 and &amp;gt;20 months). Future studies should assess the merits of biomarker selection for belzutifan treatment.<\/jats:p>","DOI":"10.36401\/jipo-24-13","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:02:13Z","timestamp":1722484933000},"page":"308-313","source":"Crossref","is-referenced-by-count":6,"title":["Successful Targeting of Somatic\n                    <i>VHL<\/i>\n                    Alterations With Belzutifan in Two Cases"],"prefix":"10.36401","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-8907","authenticated-orcid":true,"given":"Bicky","family":"Thapa","sequence":"first","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shreenivas","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Bylow","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Zi","family":"Chen","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"George","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"},{"name":"2 LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA"},{"name":"3 MCW Cancer Center and Mellowes Center for Genomic Sciences and Precision Medicine Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2024103123511544600_i2590-017X-7-4-308-b01","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"2024103123511544600_i2590-017X-7-4-308-b02","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"2024103123511544600_i2590-017X-7-4-308-b03","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2024103123511544600_i2590-017X-7-4-308-b04","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2024103123511544600_i2590-017X-7-4-308-b05","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"2024103123511544600_i2590-017X-7-4-308-b06","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"2024103123511544600_i2590-017X-7-4-308-b07","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2018.36.15_suppl.2508","article-title":"A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors","volume":"36","author":"Papadopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024103123511544600_i2590-017X-7-4-308-b08","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"2024103123511544600_i2590-017X-7-4-308-b09","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 Antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024103123511544600_i2590-017X-7-4-308-b10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"2024103123511544600_i2590-017X-7-4-308-b11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"2024103123511544600_i2590-017X-7-4-308-b12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"2024103123511544600_i2590-017X-7-4-308-b13","first-page":"3014","article-title":"VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells","volume":"62","author":"Bindra","year":"2002","journal-title":"Cancer Res"},{"key":"2024103123511544600_i2590-017X-7-4-308-b14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13073-021-00969-w","article-title":"Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na\u00efve study","volume":"13","author":"Sicklick","year":"2021","journal-title":"Genome Med"},{"key":"2024103123511544600_i2590-017X-7-4-308-b15","doi-asserted-by":"crossref","first-page":"S1329","DOI":"10.1016\/j.annonc.2023.10.090","article-title":"LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study","volume":"34","author":"Albiges","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/4\/308\/3446626\/i2590-017x-7-4-308.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/4\/308\/3446626\/i2590-017x-7-4-308.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:44Z","timestamp":1765475324000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/7\/4\/article-p308.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-13","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}